TCR-T cell therapy for advanced solid tumors with KRAS mutations
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have an advanced solid tumor (such as colorectal or lung cancer) that has not responded to standard treatments.
- Your tumor or blood test shows a KRAS G12V or G12D mutation, and your HLA type is A*11:01 or C*01:02.
- You have at least one measurable tumor and are in reasonably good health (able to care for yourself).
- You do not have certain other health conditions like active infections, severe heart problems, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy that uses your own immune cells to attack cancers with a specific gene change (KRAS G12V). It may be an option if other treatments haven't worked.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
This trial tests a new treatment made from your own immune cells that are specially trained to attack cancer cells with a specific mutation called KRAS G12V. It is for people with advanced solid tumors who have run out of standard options.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Hear when a new KRAS G12V trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.